Skip to main content
SpringerLink
Log in

Central precocious puberty: consider early treatment with gonadotropin-releasing hormone analogues to preserve maximum height

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The primary objective in the treatment of central precocious puberty is preservation of final adult height, with the greatest treatment benefit shown in children who are younger at the onset on the condition. Gonadotropin-releasing hormone analogues, the gold-standard treatment, are available in a range of preparations and delivery systems, with recent options having the benefit of less frequent dosing and potentially improved compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Nebesio TD, Eugster EA. Current concepts in normal and abnormal puberty. Curr Probl Pediatr Adolesc Health Care. 2007;37(2):50–72.

    Article  PubMed  Google Scholar 

  2. Chen M, Eugster EA. Central precocious puberty: update on diagnosis and treatment. Pediatr Drugs. 2015;17(4):273–81.

    Article  Google Scholar 

  3. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013;98(6):2198–207.

    Article  CAS  PubMed  Google Scholar 

  4. Pedicelli S, Alessio P, Scire G, et al. Routine screening by brain magnetic resonance imaging is not indicated in every girl with onset of puberty between the ages of 6 and 8 years. J Clin Endocrinol Metab. 2014;99(12):4455–61.

    Article  CAS  PubMed  Google Scholar 

  5. Ng SM. Cranial MRI scans are indicated in all girls with central precocious puberty. Arch Dis Child. 2003;88(5):414–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Miller BS, Shukla AR. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists. Clin Ther. 2010;32(10):1749–51.

    Article  PubMed  Google Scholar 

  7. Lewis KA, Goldyn AK, West KW, et al. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr. 2013;163(4):1214–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006;91(5):1862–7.

    Article  CAS  PubMed  Google Scholar 

  9. Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011;159(6):982–7.

    Article  CAS  PubMed  Google Scholar 

  10. Lee PA, Klein K, Mauras N, et al. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab. 2014;99(9):3153–9.

    Article  CAS  PubMed  Google Scholar 

  11. Hirsch HJ, Gillis D, Strich D, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics. 2005;116(6):e798–802.

    Article  PubMed  Google Scholar 

  12. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697–704.

    Article  CAS  PubMed  Google Scholar 

  13. Silverman LA, Neely EK, Kletter GB, et al. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab. 2015;100(6):2354–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Fisher MM, Lemay D, Eugster EA. Resumption of puberty in girls and boys following removal of the histrelin implant. J Pediatr. 2014;164(4):912e1–916e1.

    Google Scholar 

  15. Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol. 2010;2010:398639.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Vottero A, Pedori S, Verna M, et al. Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone. J Clin Endocrinol Metab. 2006;91(4):1284–7.

    Article  CAS  PubMed  Google Scholar 

  17. Pucarelli I, Segni M, Ortore M, et al. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab. 2003;16(7):1005–10.

    Article  CAS  PubMed  Google Scholar 

  18. Zhao X, Zhang Q. Clinical efficacy of letrozole in boys with idiopathic central precocious puberty. Chin J Contemp Pediatr. 2014;16(4):397–400.

    CAS  Google Scholar 

  19. Debiopharm International SA. Efficacy, safety, and pharmacokinetics (PK) of triptorelin 6-month formulation in patients with central precocious puberty. [ClinicalTrials.gov identifier NCT01467822] US National Institutes of Health. Clinical Trials.gov. https://clinicaltrials.gov/ct2/show/NCT01467882. Accessed 15 Jul 2015.

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Adis Medical Writers

Authors
  1. Adis Medical Writers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adis Medical Writers.

Ethics declarations

Disclosure

This article was adapted from Pediatric Drugs 2015;17(4):273–281 [2] by salaried/contracted employees of Adis/Springer and was not supported by any external funding.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Medical Writers, A. Central precocious puberty: consider early treatment with gonadotropin-releasing hormone analogues to preserve maximum height. Drugs Ther Perspect 31, 341–344 (2015). https://doi.org/10.1007/s40267-015-0238-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0238-5

Keywords

Search

Navigation